Short-course induction with boosted saquinavir monotherapy for naive patients with late-stage infection.

Abstract

This study assessed the efficacy of short-course induction treatment with saquinavir/ritonavir as boosted protease inhibitor monotherapy in antiretroviral-naive patients, before switching to conventional highly active antiretroviral therapy. Twenty-eight patients were enrolled, with baseline CD4 cell counts of 26 cells/microl and HIV RNA 5.5 log10 copies/ml. There was a median 2.5 log10 reduction in HIV RNA and 115 cell increase in CD4 cell counts after 4-8 weeks of saquinavir/ritonavir monotherapy. This treatment strategy should be evaluated further.

• Authors: Osman Ebrahim, Andrew Hill
• Journal: AIDS (London, England) (AIDS) Vol. 19 Issue 2 Pg. 211-2 (Jan 28 2005) ISSN: 0269-9370 [Print] England
• PMID: 15668549 (Publication Type: Journal Article)

Chemical References

• HIV Protease Inhibitors
• RNA, Viral
• Reverse Transcriptase Inhibitors
• Saquinavir
• Ritonavir

Topics

• Adult
• CD4 Lymphocyte Count
• Drug Administration Schedule
• Female
• HIV Infections (drug therapy)
• HIV Protease Inhibitors (administration & dosage, adverse effects)
• HIV-1
• Humans
• Male
• Middle Aged
• RNA, Viral (analysis)
• Retrospective Studies
• Reverse Transcriptase Inhibitors (therapeutic use)
• Ritonavir (administration & dosage, adverse effects)
• Saquinavir (administration & dosage, adverse effects)
• Treatment Outcome